Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 50

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 50
---
ated
Bylaws, and the applicable provisions of Delaware law. This description may not contain all of the information that is important to you
and is subject to, and is qualified in its entirety by reference to, our charter, our bylaws and the applicable provisions of Delaware
law. For information on how to obtain copies of our certificate of Incorporation and Bylaws, see “Where You Can Find More Information.”

Authorized Capital

We currently have authority to issue 80,000,000
shares of our common stock, par value of $0.0001 per share. As of February 13, 2024, 11,035,659 shares of our common stock were issued
and outstanding, held of record by 25 stockholders. Our authorized but unissued shares of common stock are available for issuance without
further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation
system on which our securities may be listed or traded.

Voting Rights

Each holder of our common stock is entitled to
one vote for each such share outstanding in the holder’s name. No holder of common stock is entitled to cumulate votes in voting
for directors.

Dividend and Liquidation Rights

The holders of outstanding shares of our common
stock are entitled to such dividends as may be declared by our board of directors out of funds legally available for such purpose. The
shares of our common stock are neither redeemable nor convertible. Holders of our common stock have no preemptive or subscription rights
to purchase any of our securities. In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled
to receive pro rata our assets, which are legally available for distribution, after payments of all debts and other liabilities. All of
the outstanding shares of our common stock are fully paid and non-assessable.

We have never paid any cash dividends on our common
stock.

Registration Rights

Under the terms of the Restricted Stock Agreement,
dated as of November 30, 2023 (the “Restricted Stock Agreement”), by and between us and PatentVest, Inc. (“PatentVest”),
we granted PatentVest rights with respect to the registration of 202,020 shares of restricted common stock issued to PatentVest (the “Restricted
Stock”) pursuant to the Restricted Stock Agreement in connection with the Consulting Services, dated as of November 30, 2023 (“Services
Agreement”),